Skip to main content
Steven Park, MD, Oncology, Charlotte, NC, Atrium Health's Carolinas Medical Center

StevenIParkMD

Oncology Charlotte, NC

Hematologic Oncology

Vice Chair for Research, Levine Cancer Institute; Clinical Professor of Medicine, Wake Forest University, North Carolina

Dr. Park is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Park's full profile

Already have an account?

Summary

  • Lymphoma expert specializing in Hodgkin lymphoma, Non-Hodgkin lymphoma, and Chronic lymphocytic leukemia.
  • Google Scholar - Steven I Park, MD

Clinical Expertise

  • Non-Hodgkin lymphoma, Hodgkin's lymphoma, Hematologic oncology, Lymphoma

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2009
  • University of Washington School of Medicine
    University of Washington School of MedicineFellowship, Oncology/Bmt, 2005 - 2009
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 2002 - 2005
  • University of California, Davis, School of Medicine
    University of California, Davis, School of MedicineClass of 2002
  • University of California, Berkeley
    University of California, BerkeleyBA

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2025
  • WA State Medical License
    WA State Medical License 2005 - 2011

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
    Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed
    Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Press Mentions

  • Follicular Lymphoma
    Follicular LymphomaSeptember 20th, 2023
  • Next Gen Innovator
    Next Gen InnovatorMarch 19th, 2021
  • Brentuximab vedotin shows promise in Hodgkin lymphoma
    Brentuximab vedotin shows promise in Hodgkin lymphomaDecember 2nd, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations